EMAD MOLAEI | Pharmaceutical Science | Young Scientist Award

Dr. EMAD MOLAEI | Pharmaceutical Science | Young Scientist Award

Clinical pharmacy resident at Tehran University of Medical Sciences, Iran.

Dr. Emad Molaei is a PGY3 Pharmacotherapy Resident at Tehran University of Medical Sciences/Imam Khomeini Hospital Complex. With a PharmD from Mashhad University of Medical Sciences and a current residency in Pharmacotherapy, he has a strong foundation in clinical pharmacy. His research focuses on nephroprotective activity, cardiovascular diseases, and COVID-19 treatments, with several first-author publications in renowned journals. Dr. Molaei’s professional experience includes roles as a community pharmacist, medication consultant, and pharmacotherapy interventionist in various hospitals. He is also the Founder and Director of the R&D Department at Daneshafza Razi Pharmaceutical Company. Recognized for his academic excellence, he has received multiple awards and honors, including being the top-ranked graduate and outstanding student at each academic level. Dr. Molaei is skilled in data analysis, scientific writing, and project management, contributing significantly to his field.

Professional Profiles:

Education 🎓

🎓 Emad Molaei is currently pursuing his Pharmacotherapy (Clinical Pharmacy) residency at the School of Pharmacy, Tehran University of Medical Sciences (TUMS), since September 2021. He completed his Pharm-D at the School of Pharmacy, Mashhad University of Medical Sciences (MUMS) in September 2021, achieving a commendable total average of 18.00. Prior to that, he earned his Diploma of Science from the Gifted Program in the National Organization for Development, with an impressive total average of 19.46 in September 2015.

Professional Experience

👨‍⚕️ Emad Molaei’s professional journey includes his current role as a PGY3 Pharmacotherapy Resident at Tehran University of Medical Sciences / Imam Khomeini Hospital Complex. He has extensive clinical experience as a Community Pharmacist at 13-Aban TUMS Community Chain Pharmacy in Tehran and Razavi Pharmaceutical Service Institute in Mashhad. Additionally, he has served as a Medication Consultant at the Drug and Poison Information Center (DPIC) in Tehran and has been involved in pharmacotherapy interventions at several hospitals, including Imam Khomeini, Shariati, Sina, and Roozbeh Hospitals in Tehran. Emad also has experience working in the satellite pharmacy of the critical care department at Sina Hospital and initiated activities in the clean room dedicated to cytotoxic drug production at the Cancer Institute, Imam Khomeini Hospital Complex. Beyond his clinical roles, he has contributed as a Research Assistant and Teacher Assistant in Pharmacotherapy, Pharmacology, and Toxicology.

Research Interest

🔬 Emad Molaei’s research interests span across various aspects of clinical pharmacy and pharmacotherapy. He is particularly focused on the nephroprotective activity of natural products against chemical toxicants and the role of the Nrf2/ARE signaling pathway. Emad also investigates the therapeutic potential of Resolvin D1 in Acute Respiratory Distress Syndrome and explores emerging therapeutic targets for cardiovascular diseases, including the LKB1 pathway and the Mas receptor. Additionally, he is involved in clinical studies evaluating the efficacy and safety of treatments for burn patients, such as silver sulfadiazine 1%-cerium nitrate 2.2% cream. Emad’s work also extends to the treatment of COVID-19 with Remdesivir in special populations, showcasing his commitment to addressing critical health issues through innovative research.

Award and Honors

🏆 Emad Molaei has received numerous awards and honors throughout his academic and professional career. He was recognized as the most outstanding student at each academic level and graduated as the top-ranked student from the Mashhad Faculty of Pharmacy. Emad also achieved the highest rank in the pharmacy specialty examination and is a member of the Brilliant Academic Talent Program. His presentation skills have been acknowledged with the best poster award at the 12th subspecialty congress of Iranian burn physicians. Emad’s dedication to excellence is further demonstrated by his active membership in various professional organizations and his role as the Founder and Director of the R&D Department at Daneshafza Razi Pharmaceutical Company.

Research Skills

🧪 Emad Molaei possesses a robust set of research skills. He is proficient in data analysis using software such as SPSS, GraphPad Prism, and Sigma Plot. His scientific writing abilities are well-honed, and he is adept with EndNote and Microsoft Office tools. Emad’s project management skills are complemented by his experience as a Research Assistant and Teacher Assistant in Pharmacotherapy, Pharmacology, and Toxicology. His clinical research experience includes participation in multiple clinical trials and studies, showcasing his ability to handle complex research projects effectively.

Publications by Emad Molaei

  1. Remdesivir: Treatment of COVID-19 in Special Populations
    • Authors: Molaei, E., Molaei, A., Hayes, A.W., Karimi, G.
    • Journal: Naunyn-Schmiedeberg’s Archives of Pharmacology
    • Year: 2024
    • Citations: 1
  2. Mas Receptor: A Potential Strategy in the Management of Ischemic Cardiovascular Diseases
    • Authors: Molaei, A., Molaei, E., Hayes, A.W., Karimi, G.
    • Journal: Cell Cycle
    • Year: 2023
    • Citations: 5
  3. LKB1: An Emerging Therapeutic Target for Cardiovascular Diseases
    • Authors: Molaei, A., Molaei, E., Sadeghnia, H., Hayes, A.W., Karimi, G.
    • Journal: Life Sciences
    • Year: 2022
    • Citations: 13
  4. Resolvin D1: Therapeutic Target in Acute Respiratory Distress Syndrome
    • Authors: Molaei, E., Molaei, A., Hayes, A.W., Karimi, G.
    • Journal: European Journal of Pharmacology
    • Year: 2021
    • Citations: 18
  5. Nephroprotective Activity of Natural Products Against Chemical Toxicants: The Role of Nrf2/ARE Signaling Pathway
    • Authors: Molaei, E., Molaei, A., Abedi, F., Hayes, A.W., Karimi, G.
    • Journal: Food Science and Nutrition
    • Year: 2021
    • Citations: 23

 

Amedeo De Nicolò | Pharmaceutical Science | Best Researcher Award

Dr. Amedeo De Nicolò | Pharmaceutical Science | Best Researcher Award

Ricercatore a Tempo Determinato Cat. B at University of Turin, Italy.

Amedeo De Nicolò, born on April 20, 1987, is an Italian researcher currently affiliated with the University of Turin. He holds a PhD in Medicine and Experimental Therapy and a Master’s degree in Cellular and Molecular Biology. De Nicolò specializes in pharmacology, focusing on pharmacokinetics and pharmacogenetics. His research interests include developing bioanalytical methods for Therapeutic Drug Monitoring (TDM) and studying drug interactions and pharmacokinetic/pharmacodynamic evaluations. Throughout his career, he has contributed significantly to clinical pharmacology through various research projects, publications, and participation in international collaborations. In addition to his research, De Nicolò has a strong teaching background, having taught pharmacology courses at the University of Turin and participated in a Master’s program related to biological product control in the industry. He is also an active member of several scientific societies and working groups, including the Italian Society of Pharmacology and the international research consortium VirTUAL.

Professional Profiles:

Education

Amedeo De Nicolò completed his PhD in Medicine and Experimental Therapy from the University of Turin in January 2017. His dissertation focused on the “Pharmacokinetics and Pharmacogenetics of Anti-HCV Treatments,” receiving positive evaluations. Prior to his doctorate, he earned a Master’s degree in Cellular and Molecular Biology, with a Biomedical curriculum, from the same university in October 2011. His master’s thesis titled “Identificazione di Nuovi Parametri Farmacocinetici per la Valutazione Precoce del Rischio di Anemizzazione in Pazienti Sottoposti a Terapia Anti-HCV Standard” was awarded the highest honors, graduating with a score of 110/110 cum laude. Additionally, he holds a Bachelor’s degree in Biological Sciences from the University of Turin, obtained in December 2009. Throughout his academic journey, De Nicolò acquired substantial competencies in biological sciences, clinical pharmacology, laboratory medicine, and statistics. In August 2020, he also achieved professional licensure as a Biologist, further solidifying his qualifications in the field.

Professional Experience

Amedeo De Nicolò is currently a fixed-term researcher (type B) at the University of Turin, specializing in pharmacokinetics and pharmacogenetics. He has been involved in clinical pharmacology research since his internship for his master’s thesis in 2010-2011. From March 2022, he has held his current position at the Department of Medical Sciences, focusing on the development, validation, and application of bioanalytical methods in liquid chromatography for Therapeutic Drug Monitoring (TDM). Prior to this, he was a research fellow from July 2017 to February 2022 at the same institution. During this period, he contributed significantly to pharmacokinetic studies, particularly related to drug-drug interactions and the pharmacokinetic/pharmacodynamic evaluations of antiviral and tuberculosis treatments under the international DERIVE project. De Nicolò has also provided clinical consultancy in interpreting TDM results and has actively participated in the ISO certification processes for biomedical diagnostic kit validations. His extensive experience includes conducting routine drug analysis and providing clinical pharmacological advice since 2012. In addition to his research, he has taught pharmacology modules at the University of Turin for various nursing programs and a master’s course, contributing to academic education alongside his research duties.

Research Interest

Amedeo De Nicolò’s research interests lie primarily in the fields of pharmacokinetics and pharmacogenetics, focusing on clinical pharmacology. His work involves the development, validation, and application of bioanalytical methods using liquid chromatography for Therapeutic Drug Monitoring (TDM). He is particularly interested in studying drug-drug interactions, evaluating pharmacokinetic and pharmacodynamic relationships, and interpreting clinical data through statistical analysis. De Nicolò is also engaged in research related to the pharmacokinetics of antiviral treatments and the intracellular measurement of anti-infective drugs. His involvement in international research consortia, such as VirTUAL and the COVID-19 Mass Spectrometry Coalition, highlights his commitment to advancing knowledge in these areas. Additionally, De Nicolò’s research extends to the standardization of methodological approaches in TDM, contributing to the enhancement of clinical practices and patient care.

Award and Honors

Amedeo De Nicolò has received several notable awards and honors throughout his career, reflecting his significant contributions to the field of clinical pharmacology. He obtained the National Scientific Qualification as Associate Professor in the sector of Pharmacology, Clinical Pharmacology, and Pharmacognosy (05/G1) on November 6, 2018. This achievement recognizes his expertise and leadership in pharmacological research. Furthermore, De Nicolò became a licensed Biologist on August 12, 2020, showcasing his professional qualifications in biological sciences. His work is also distinguished by his active membership in prominent scientific societies, such as the Italian Society of Pharmacology (SIF) and the Italian Society of Clinical Biochemistry (SIBioC), where he continues to contribute to the advancement of pharmacological sciences.

Research skills

Amedeo De Nicolò possesses a robust set of research skills honed through extensive experience in clinical pharmacology. His expertise includes the development, validation, and application of bioanalytical methods in liquid chromatography for Therapeutic Drug Monitoring (TDM), adhering to ISO 9001 and ISO 13485 standards. He excels in pharmacokinetics and pharmacogenetics, focusing on drug interactions, efficacy, and toxicity. De Nicolò is proficient in statistical analysis and the interpretation of clinical and pharmacogenetic data. Additionally, he has a strong background in conducting and coordinating pharmacokinetic studies, including those involving intracellular drug measurements and therapeutic drug monitoring in various medical contexts. His skills are complemented by his ability to write and publish scientific articles, contributing significantly to the body of knowledge in clinical pharmacology.

Publications

  1. Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?
    • Authors: Cusato, J., Manca, A., Palermiti, A., Boglione, L., D’Avolio, A.
    • Year: 2024
    • Citations: 0
  2. Cannabinoid levels description in a cohort of patients with chronic and neuropathic pain treated with Cannabis decoction: A possible role of TDM
    • Authors: Manca, A., Valz, C., Chiara, F., Cusato, J., D’Avolio, A.
    • Year: 2024
    • Citations: 0
  3. Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir with Rifampicin
    • Authors: Gausi, K., Mugerwa, H., Siccardi, M., Denti, P., Waitt, C.
    • Year: 2024
    • Citations: 1
  4. Comparative Performance Assessment of Novel Fluorescence Immunoassay POCTs for Measuring Circulating Levels of Vitamin-D
    • Authors: Palermiti, A., Manca, A., Mastrantonio, F., De Nicolò, A., D’Avolio, A.
    • Year: 2024
    • Citations: 0
  5. Pharmacokinetics of tecovirimat in subjects with Mpox
    • Authors: Tempestilli, M., Mondi, A., D’Avolio, A., Vaia, F., Antinori, A.
    • Year: 2024
    • Citations: 0
  6. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study
    • Authors: Stroffolini, G., Dodaro, V., De Nicolò, A., D’Avolio, A., Boglione, L.
    • Year: 2024
    • Citations: 0
  7. Pharmacokinetics and pharmacogenetics of high-dosage tedizolid for disseminated nocardiosis in a lung transplant patient
    • Authors: Corcione, S., Vita, D., De Nicolò, A., D’Avolio, A., De Rosa, F.G.
    • Year: 2023
    • Citations: 0
  8. Experimental pharmacology in precision medicine
    • Authors: Urbaniak, A., Thummel, K.E., Alade, A.N., Sheppard, D.N., Jarvis, M.F.
    • Year: 2023
    • Citations: 1
  9. Stability Study of Fosfomycin in Elastomeric Pumps at 4 °C and 34 °C: Technical Bases for a Continuous Infusion Use for Outpatient Parenteral Antibiotic Therapy
    • Authors: Manca, A., Palermiti, A., Mula, J., De Nicolò, A., D’Avolio, A.
    • Year: 2023
    • Citations: 0
  10. Vitamin D impact in affecting clozapine plasma exposure: A potential contribution of seasonality
    • Authors: Manca, A., Mula, J., Palermiti, A., Cusato, J., D’Avolio, A.
    • Year: 2023
    • Citations: 0